Parkinson’s Disease Treatment Market- our new study reveals trends, R&D progress, and predicted revenues
Where the Parkinson’s Disease Treatment is market heading? If you are involved in this industry you must read this newly updated report. Visiongain’s report shows you the potential revenues streams to 2030, assessing data, trends, opportunities and business prospects there.
Discover how to stay ahead
Our 200-page report provides 80 tables, 55 charts, and graphs. Read on to discover the most lucrative areas in the industry and the future market prospects. Our study lets you assess forecasted sales at overall world market and regional level. See financial performance of companies, trends, opportunities, and revenue growth. Much opportunity remains in this growing Parkinson’s Disease Treatment market. See how to exploit the opportunities.
Forecasts to 2030 and other analyses reveal the commercial prospects
– In addition to revenue forecasting to 2030, our new study provides you with recent results, growth rates, and market shares, key player positioning, and an exhaustive product portfolio comparison of key vendors
– You find original analyses, with business outlooks and developments which would be useful to tap potential business areas for key players
– Discover qualitative analyses (including market dynamics, drivers, opportunities, restraints and challenges, SWOT analysis), product profiles and commercial developments.
Discover sales predictions for the world market and submarkets
Along with revenue prediction for the overall world market, there are one segmentations of the Parkinson’s Disease Treatment market, with forecasts for product, application, and end use each forecasted at a global and regional level.
Global Parkinson’s Disease Treatment 2020-2030 is segmented on the basis of Drug Class, Patient Care Setting, and geography.
Global Parkinson’s Disease Treatment Market By Drug Class:
– Carbidopa/Levodopa
– Dopamine Receptor Agonists
– Mao Inhibitors
– Comt Inhibitors
– Others
Global Parkinson’s Disease Treatment Market By Patient Care Setting:
– Hospitals
– Clinics
Global Parkinson’s Disease Treatment Market By Region:
– North America
– U.S.
– Canada
– Europe
– Germany
– France
– UK
– Italy
– Netherlands
– Rest of Europe
– Asia Pacific
– India
– China
– Japan
– Rest of Asia Pacific
– Central & South America
– Middle East & Africa
How the Parkinson’s Disease Treatment Market report helps you
In summary, our 200-page report provides you with the following knowledge:
– Revenue forecasts to 2030 for each of the above mentioned segments each forecasted at a global and regional level– growth of all segments on regional level helps to understand most lucrative Patient Care Setting/ Drug Class.
– Revenue forecasts to 2030 for 5 regional and 10 key national markets – the report highlights market growth prospects for key countries such as the U.S., Canada, Germany, UK, France, Italy, Netherlands, China, Japan, and India. The report also highlights growth potential in Central & South America as well as Middle East & Africa.
– Prospects for established firms and those seeking to enter the market– including company profiles for over 10 of the major companies involved in the Parkinson’s Disease Treatment market
Find quantitative and qualitative analyses with independent predictions. Receive information that only our report contains, staying informed with this invaluable business intelligence.
Information found nowhere else
With our newly report title, you are less likely to fall behind in knowledge or miss out on opportunities. See how our work could benefit your research, analyses, and decisions. Visiongain’s study is for everybody needing commercial analyses for the Parkinson’s Disease Treatment market and leading companies. You will find data, trends and predictions.
Get our report today The Parkinson’s Disease Treatment Market Forecast 2020-2030: Forecasts by Drug Class (Carbidopa/Levodopa/ Dopamine Receptor Agonists/ Mao Inhibitors/ Comt Inhibitors/others) by Patient Care Setting (Hospitals and Clinics) by and Geography.
The Parkinson’s Disease Treatment Market 2020-2030 report will be of value to anyone who wants to better understand the market and its various segments. It will be useful for businesses who wish to better comprehend the part of the market they are already involved in, or those wishing to enter or expand into a different regional or technical part of the Parkinson’s disease industry.
Visiongain is a trading partner with the US Federal Government
CCR Ref number: KD4R6
Do you have any custom requirements we can help you with? Any need for specific country, geo region, market segment or specific company information? Contact us today, we can discuss your needs and see how we can help: sara.peerun@visiongain.com
1. Report Overview
1.1. Global Parkinson’s Disease Treatment Market Overview
1.2. Why You Should Read This Report
1.3. How This Report Delivers
1.4. Key Questions Answered by This Analytical Report Includes:
1.5. Who is This Report For?
1.6. Methodology
1.6.1. Primary Research
1.6.2. Secondary Research
1.7. Frequently Asked Questions (FAQ)
1.8. Associated Visiongain Reports
1.9. About Visiongain
2. Introduction to Parkinson’s Disease Treatment Market
2.1. Market definition
2.2. Scope & Segmentation
2.2.1. Drug Class
2.2.2. Regional Scope
2.3. Assumptions For The Study
2.4. List of Data Sources
3. Parkinson’s Disease Treatment Market Dynamics
3.1. Introduction
3.2. Market dynamics
3.2.1. Market drivers
3.2.1.1. Rising incidence of Parkinson’s in geriatric population
3.2.1.2. Increasing life expectancy globally
3.2.1.3. Government Funding for Research
3.2.2. Market restraints
3.2.2.1. Availability of Alternative Treatments
3.2.3. Market opportunities
3.2.3.1. Strong Drug Pipeline
3.3. Porters Five Forces Model
3.3.1. Bargaining power of buyer
3.3.1.1. High cost of drugs
3.3.1.2. Low approval rates
3.3.2. Bargaining power of supplier
3.3.2.1. Capital intensive R&D
3.3.2.2. Stringent approval process
3.3.3. Threat of substitutes
3.3.3.1. Nourianz
3.3.4. Threat of new entrants
3.3.4.1. Capital intensive research
3.3.5. Industry rivalry
3.3.5.1. Presence of well-established pharmaceutical giants
3.4. SWOT Analysis
3.4.1. Strength
3.4.1.1. Limited number of drugs available for disease management
3.4.2. Weakness
3.4.2.1. Low approval rates
3.4.3. Opportunities
3.4.3.1. High potential markets in asia pacific
3.4.4. Threats
3.4.4.1. Regulatory affairs
3.5. PESTEL Analysis
3.5.1. Political & legal landscape
3.5.2. Economic landscape
3.5.3. Social landscape
3.5.4. Technological landscape
3.5.5. Environmental landscape
3.6. Mergers and Acquisitions
3.7. Entry of New Market Players
3.8. Parkinson prevalence by region
3.8.1. North America
3.8.2. Europe
3.8.3. Asia Pacific
3.8.4. CSA
3.8.5. MEA
3.9. Parkinson drugs timeline, 2000-2020
4. Parkinson’s Disease Treatment Market By Drug Class 2020 – 2030
4.1. Parkinson’s Disease Treatment Market, Annual Growth Rate Comparison, By Drug Class
4.2. Global Parkinson’s Disease Treatment Market, Market Share Comparison, By Drug Class (2020 & 2030)
4.3. Global Parkinson’s Disease Treatment Market Size and Forecast, By Drug Class
4.3.1. Carbidopa/Levodopa Revenue Forecast 2020-2030
4.3.2. Dopamine Receptor Agonists Revenue Forecast 2020-2030
4.3.3. Mao Inhibitors Revenue Forecast 2020-2030
4.3.4. Comt Inhibitors Revenue Forecast 2020-2030
4.3.5. Others Revenue Forecast 2020-2030
5. Parkinson’s Disease Treatment Market By Patient Care Setting 2020 – 2030
5.1. Parkinson’s Disease Treatment Market, Annual Growth Rate Comparison, By Patient Care Setting
5.2. Global Parkinson’s Disease Treatment Market, Market Share Comparison, By Patient Care Setting (2020 & 2030)
5.3. Global Parkinson’s Disease Treatment Market Size and Forecast, By Patient Care Setting
5.3.1. Hospitals Revenue Forecast 2020-2030
5.3.2. Clinics Revenue Forecast 2020-2030
6. Parkinson’s Disease Treatment Market By Region 2020 – 2030
6.1. Global Parkinson’s Disease Treatment Market, Annual Growth Rate Comparison, By Region
6.2. Global Parkinson’s Disease Treatment Parkinson’s Disease Treatment Market, Market Share Comparison, By Region (2020 & 2030)
6.3. Global Parkinson’s Disease Treatment Market Size and Forecast, By Region
6.4. North America Revenue Forecast 2020-2030
6.4.1. Market Size and Estimation by Drug Class 2020-2030
6.4.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.4.3. U.S. Revenue Forecast 2020-2030
6.4.3.1. Market Size and Estimation by Drug Class 2020-2030
6.4.3.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.4.4. Canada Revenue Forecast 2020-2030
6.4.4.1. Market Size and Estimation by Drug Class 2020-2030
6.4.4.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.5. Europe Revenue Forecast 2020-2030
6.5.1. Market Size and Estimation by Drug Class 2020-2030
6.5.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.5.3. Germany Revenue Forecast 2020-2030
6.5.3.1. Market Size and Estimation by Drug Class 2020-2030
6.5.3.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.5.4. UK Revenue Forecast 2020-2030
6.5.4.1. Market Size and Estimation by Drug Class 2020-2030
6.5.4.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.5.5. France Revenue Forecast 2020-2030
6.5.5.1. Market Size and Estimation by Drug Class 2020-2030
6.5.5.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.5.6. Italy Revenue Forecast 2020-2030
6.5.6.1. Market Size and Estimation by Drug Class 2020-2030
6.5.6.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.5.7. Netherlands Revenue Forecast 2020-2030
6.5.7.1. Market Size and Estimation by Drug Class 2020-2030
6.5.7.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.6. Asia Pacific Revenue Forecast 2020-2030
6.6.1. Market Size and Estimation by Drug Class 2020-2030
6.6.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.6.3. China Revenue Forecast 2020-2030
6.6.3.1. Market Size and Estimation by Drug Class 2020-2030
6.6.3.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.6.4. Japan Revenue Forecast 2020-2030
6.6.4.1. Market Size and Estimation by Drug Class 2020-2030
6.6.4.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.6.5. India Revenue Forecast 2020-2030
6.6.5.1. Market Size and Estimation by Drug Class 2020-2030
6.6.5.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.7. Central & South America Revenue Forecast 2020-2030
6.7.1. Market Size and Estimation by Drug Class 2020-2030
6.7.2. Market Size and Estimation by Patient Care Setting 2020-2030
6.8. Middle East & Africa Revenue Forecast 2020-2030
6.8.1. Market Size and Estimation by Drug Class 2020-2030
6.8.2. Market Size and Estimation by Patient Care Setting 2020-2030
7. Competitive Landscape
7.1. Wockhardt
7.1.1. Company overview
7.1.2. Drug Class portfolio
7.1.3. Financial performance
7.1.4. Recent strategies
7.2. Acadia
7.2.1. Company overview
7.2.2. Drug Class portfolio
7.2.3. Financial performance
7.2.4. Recent strategies
7.3. UCB
7.3.1. Company overview
7.3.2. Drug Class portfolio
7.3.3. Financial performance
7.3.4. Recent strategies
7.4. Sun Pharma
7.4.1. Company overview
7.4.2. Drug Class portfolio
7.4.3. Financial performance
7.4.4. Recent strategies
7.5. Lundbeck
7.5.1. Company overview
7.5.2. Drug Class portfolio
7.5.3. Financial performance
7.5.4. Recent strategies
7.6. Valeant Pharmaceuticals
7.6.1. Company overview
7.6.2. Drug Class portfolio
7.6.3. Financial performance
7.6.4. Recent strategies
7.7. Abbvie
7.7.1. Company overview
7.7.2. Drug Class portfolio
7.7.3. Financial performance
7.7.4. Recent strategies
7.8. Impax
7.8.1. Company overview
7.8.2. Drug Class portfolio
7.8.3. Financial performance
7.8.4. Recent strategies
7.9. Boehringer Ingelheim
7.9.1. Company overview
7.9.2. Drug Class portfolio
7.9.3. Financial performance
7.9.4. Recent strategies
7.10. Teva
7.10.1. Company overview
7.10.2. Drug Class portfolio
7.10.3. Financial performance
7.10.4. Recent strategies
7.11. Novartis
7.11.1. Company overview
7.11.2. Drug Class portfolio
7.11.3. Financial performance
7.11.4. Recent strategies
7.12. Merck
7.12.1. Company overview
7.12.2. Drug Class portfolio
7.12.3. Financial performance
7.12.4. Recent strategies
7.13. GSK
7.13.1. Company overview
7.13.2. Drug Class portfolio
7.13.3. Financial performance
7.13.4. Recent strategies
8. Conclusions
8.1. Key Findings in the Parkinson’s Disease Treatment Market
8.2. Recommendations for the Parkinson’s Disease Treatment Market
9. Glossary
List of Tables:
1. Global Parkinson’s Disease Treatment Market, 2020 & 2030 (USD Million)
2. North America Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
3. North America Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
4. U.S. Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
5. U.S. Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
6. Canada Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
7. Canada Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
8. Europe Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
9. Europe Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
10. Germany Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
11. Germany Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
12. UK Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
13. UK Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
14. France Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
15. France Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
16. Netherlands Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
17. Netherlands Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
18. Italy Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
19. Italy Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
20. APAC Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
21. APAC Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
22. China Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
23. China Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
24. Japan Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
25. Japan Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
26. India Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
27. India Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
28. CSA Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
29. CSA Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
30. MEA Parkinson’s Disease Treatment Market, by Drug Class, 2020 – 2030 (USD Million)
31. MEA Parkinson’s Disease Treatment Market, by Patient Care Setting, 2020 – 2030 (USD Million)
List of Figures
1. Research Methodology
2. Market Size Estimation Methodology
3. Forecasting Methodology
4. Global Parkinson’s Disease Treatment Market, impact analysis
5. SWOT Analysis
6. Global Parkinson’s Disease Treatment Market, Company Market Share Analysis
7. Global Parkinson’s Disease Treatment Market Segmentation
8. Global Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Drug Class, 2020-2030
9. Global Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Patient Care Setting, 2020-2030
10. North America Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Drug Class, 2020-2030
11. North America Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Patient Care Setting, 2020-2030
12. Europe Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Drug Class, 2020-2030
13. Europe Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Patient Care Setting, 2020-2030
14. APAC Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Drug Class, 2020-2030
15. APAC Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Patient Care Setting, 2020-2030
16. CSA Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Drug Class, 2020-2030
17. CSA Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Patient Care Setting, 2020-2030
18. MEA Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Drug Class, 2020-2030
19. MEA Parkinson’s Disease Treatment Market Share and Y-o-Y Growth, by Patient Care Setting, 2020-2030
GSK
Merck
Sun Pharma
Wockhardt
Novartis
Impax
Abbvie
Valeant Pharmaceuticals
Lundbeck
Teva
Boehringer Ingelheim
Acadia
UCB